- Nano cap Ampio Pharmaceuticals (NYSE:AMPE) slips 5% premarket on light volume in reaction to its announcement that the FDA does not want it to start its confirmatory trial of Ampion in patients with knee osteoarthritis without the agency's agreement on the trial design.
- The company says it agrees the regulator's comments and has submitted a revised protocol for review.
- Previously: FDA requires additional study of Ampio Pharma's Ampion to support marketing application; shares down 11% premarket (Dec. 13, 2018)
Ampio not quite there with confirmatory study of Ampion; shares down 5% premarket
Recommended For You
About AMPE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AMPE | - | - |
Ampio Pharmaceuticals, Inc. |